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Abstract
Background: Increased myocardial triglyceride (TG) content has been recognized as a risk factor for cardiovascular
disease. However, its relation with cardiac function in patients on recovery from acute heart failure (HF) remains
unclear. In this cross-sectional study, we sought to investigate the association between myocardial TG content
measured on magnetic resonance spectroscopy (1H-MRS) and left ventricular (LV) function assessed on
cardiovascular magnetic resonance (CMR) in patients who were hospitalized with HF.
Methods: A total of 50 patients who were discharged after hospitalization for acute HF and 21 age- and sex-
matched controls were included in the study. Myocardial TG content and LV parameters (function and mass) were
measured on a 3.0 T MR scanner. Fatty acid (FA) and unsaturated fatty acid (UFA) content was normalized against
water (W) using the LC-Model algorithm. The patient population was dichotomized according to the left ventricular
ejection fraction (LVEF, <50 % or ≥ 50 %).
Results: H-MRS data were available for 48 patients and 21 controls. Of the 48 patients, 25 had a LVEF <50 % (mean,
31.2 %), whereas the remaining 23 had a normal LVEF (mean, 60.2 %). Myocardial UFA/W ratio was found to differ
significantly in patients with low LVEF, normal LVEF, and controls (0.79 % vs. 0.21 % vs. 0.14 %, respectively, p = 0.02).
The myocardial UFA/TG ratio was associated with LV mass (r = 0.39, p < 0.001) and modestly related to LV end-diastolic
volume (LVEDV; r = 0.24, p = 0.039). We also identified negative correlations of the myocardial FA/TG ratio with both LV
mass (r = -0.39, p < 0.001) and LVEDV (r = -0.24, p = 0.039).
Conclusions: As compared with controls, patients who were discharged after hospitalization for acute HF had increased
myocardial UFA content; furthermore, UFA was inversely related with LVEF, LV mass and, to a lesser extent, LVEDV. Our
study may stimulate further research on the measure of myocardial UFA content by 1H-MRS for outcome prediction.
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Background
Heart failure (HF), a clinical syndrome in which the heart is
unable to provide sufficient blood flow to meet metabolic
requirements, is a major public health concern because of
its high prevalence, poor prognosis, and significant health-
care costs [1]. In Taiwan, cardiovascular-related deaths have
increased significantly from 4.3 to 6.5 persons per
million population between 1981 and 2009 [2]. Des-
pite major efforts to improve treatment of acute HF in the
hospital setting, the 3 month readmission rates remain as
high as 25–50 % and the 5 year survival is less than 50 %
[1]. Consequently, more effective therapeutic targets and
improved management approaches are urgently needed.
Although a beating heart utilizes fatty acids as a pri-
mary source of energy [3], an increased level of myocar-
dial triglyceride (TG) content results in lipotoxicity and
may contribute to the development of cardiac dysfunc-
tion [4–6]. Consequently, the in vivo measurement of
myocardial TG content and metabolic activity has been
proposed for guiding appropriate treatment in hospital-
ized HF patients [7].
Proton magnetic resonance spectroscopy (1H-MRS) is
increasingly being used as a non-invasive, non-radiation
exposure technique for the clinical assessment of myo-
cardial lipid content [8]. In recent years, the use of high-
field scanners (3.0 T) has improved the chemical shift
resolution and signal-to-noise ratio of cardiac 1H-MRS,
ultimately allowing the discrimination between fatty
acids (FA) and unsaturated fatty acids (UFA) deposition
in the myocardium. However, studies focusing on the
clinical usefulness of 1H-MRS imaging for the metabolic
evaluation of HF patients are particularly lacking. We
therefore designed the current cross-sectional investiga-
tion to analyze the associations between myocardial TG
content measured on 1H-MRS and left ventricular (LV)
function assessed on cardiovascular magnetic resonance
(CMR) in patients who were hospitalized with HF. We
demonstrate that patients who were discharged after
hospitalization for acute HF had increased myocardial
UFA content, which was inversely related with LV ejec-
tion fraction (LVEF), LV mass and, to a lesser extent, LV
end-diastolic volume (LVEDV).
Methods
Ethics, consent and permissions
This study was approved by our institutional review board
(IRB 102-2772A3), and the study participants provided
their written informed consent. The study was registered
at ClinicalTrials.gov (Identifier: NCT02378402).
Study design and participants
This study was conducted at a tertiary referral hospital
with a dedicated HF center. The inclusion criteria for pa-
tients were as follows: (1) having been discharged from
the Keelung Chang Gung Memorial Hospital following
hospitalization for acute HF in the 6–12 months preced-
ing the study; (2) absence of known coronary artery dis-
ease involving the cardiac septum; (3) age between 20
and 70 years; (4) willingness to comply with the standard
treatment and follow-up schedule proposed by the HF
center; (5) willingness to provide written informed con-
sent. Patients were excluded if they met one of the fol-
lowing criteria: (1) lack of compliance or inability to
follow treatment or scheduled visits; (2) contraindica-
tions to CMR (e.g., cardiac pacemaker, metal implants,
claustrophobia, or inability to cooperate with the exam-
iners); (3) pregnancy or breastfeeding; and (4) positive
history of open cardiac surgery. A multidisciplinary team
centrally reviewed medical records of eligible patients to
ensure the enrollment quality. The day before their
CMR, the study participants were requested to fast over-
night [9]. The patient population was dichotomized ac-
cording to the LVEF at the time of CMR, as follows: low
LVEF, <50 % and normal LVEF, ≥ 50 %. Age- and sex-
matched volunteers without a history of cardiovascular
disorders served as controls. The reproducibility be-
tween two repeated 1H-MRS measures within a single
CMR session was assessed in the first 10 control sub-
jects enrolled in the study. Clinical variables and serum
lipid parameters (total cholesterol, high-density lipopro-
tein cholesterol, low-density lipoprotein cholesterol, very
low-density lipoprotein cholesterol, and triglycerides)
were collected within 1 month of CMR.
CMR
CMR was performed on a 3.0-Tesla Skyra scanner (Siemens
Medical Systems, Erlangen, Germany) operating on the
VD13 platform, with an 18-channel phased-array receiver
body coil. Short-axis (contiguous 8-mm-thick slices) and
standard long-axis views (2-, 3- and 4-chamber views) cine
images were obtained using Steady-State Free Precession
(SSFP) cine imaging with the following parameters: repeti-
tion time, 3.4 ms; echo time, 1.2 ms; matrix, 256 × 256; field
of view, 34 to 40 cm.
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1H-MRS
Short-axis and 4-chamber SSFP cine images were obtained
to prescribe the locations of MRS voxels with saturation
slabs across subcutaneous and pericardial fat. The B0 shim-
ming parameters were optimized with a (breath-hold) rapid
B0 mapping method. Localized 1D MRS with Point-
Resolved SpectroScopy (PRESS) was performed by selecting
a 2 × 2 × 1-cm3 spectroscopic volume within the interven-
tricular septum with the following parameters: nominal TR/
TE, 550 ms/33 ms; 64 averages; window size, 1024 points;
bandwidth, 2000 Hz. Cardiac gating was determined from
the manufacturer’s vector ECG signal, with the first pulse of
the PRESS localization sequence being around the end-
systole phase (before the beginning of the cardiac motion)
[9–17]. The trigger delay was optimized on cine images to
avoid signal contamination from the blood pool for accom-
plishing water suppression [18]. Myocardial TG signals and
the water signal were acquired from spectra with water sup-
pression and without water suppression, respectively. Pa-
tients breathed freely during spectroscopic acquisition. The
spectroscopic signals were acquired at end-systole and end-
expiration with electro-cardiographic triggering and respira-
tory navigator gating. Respiratory gating was triggered with
a navigator placed near the right dome of the liver close to
the heart. We used Prospective Acquisition Correction navi-
gator echoes (PACE) to control for the respiratory move-
ment (within a pre-defined acceptance window of 5 mm
around end expiration) and an electrocardiograph-derived
R wave to control for cardiac pulsation. The CMRS scan
time was approximately 10 min. To assess reproducibility,
we measured with 3 T 1H-MRS the composition of a phan-
tom consisting of both UFAs and saturated FAs. Clinical
MRS measures were repeated in the first ten control sub-
jects within a single CMR session, with spectra reacquired
using the same localizations and settings.
Image analysis
LVEF was calculated from short-axis cine LV images with
vendor-provided post-processing software (Argus Viewer
and Function, Siemens Medical Solutions, Erlangen,
Germany) on a separate workstation. LV endocardial and
epicardial borders were traced manually at end-diastole
and end-systole on the short-axis cine images to deter-
mine the LVEF and end-diastolic LV mass for each slice,
and the respective EDV, end-systolic volume (ESV) were
obtained from the tracing. The LV global function index
(LVGFI) was calculated using the following formula:
LVGFI ¼ LVSV=LVEDV þ LVESVÞ=2
þ LV mass=1:05  100
1H-MRS spectra were analyzed using the LC Model
software (Provencher, Ontario, CA, USA), which
automatically calculates a weighted coherent average
over the multiple channels and analyzes the resultant
spectra (Fig. 1). The metabolites of interest were deter-
mined using simulated macromolecule resonances, with
their concentrations ranging from 0 to 10 parts per mil-
lion (ppm). The Cramer-Rao lower bounds (CRLB),
which simultaneously account for both resolution and
noise, were used as an estimated error in metabolite
quantification. All of the spectra in the single scan ses-
sion were included and averaged, whereas metabolite es-
timates were excluded from the analysis when the CRLB
value exceeded the 50 % range. The variation of the
water signal amplitude in the individual spectra acquired
without water suppression was calculated. We quantified
the total myocardial TG resonance as well as its compo-
nents including FA (lipid resonances δ 0.9, 1.3 and
1.6 ppm) and UFA (lipid resonance δ 2.1 and 2.3, 2.8,
5.3 ppm) from water-suppressed spectra. We also deter-
mined the water resonance (~ δ 4.7 ppm) from spectra
without water suppression. Myocardial TG content rela-
tive to water as well as relative amounts of myocardial
TG was calculated from the available data.
Statistical analysis
The study variables were summarized using descriptive
statistics. A Bland-Altman plot was used to assess the
reproducibility between two-repeated 1H-MRS measures
within a single CMR session in the first ten subjects in-
cluded in the study [19]. Continuous variables were ana-
lyzed with the Mann–Whitney U test (two-group
comparisons) or one-way analysis of variance (ANOVA,
three-group comparisons). Bivariate correlation analyses
(Spearman’s rho) were performed to test the association
between LV parameters and myocardial TG content. A
value of p < 0.05 (two-sided) was considered statistically
significant.
Results
Clinical and biochemical characteristics of the study
participants
A total of 50 patients who were discharged after
hospitalization for acute HF and 21 age- and sex-matched
normal controls were included in the study. The flow
chart of patient selection algorithm, and the numbers of
participants recruited in each subgroup is summarized in
Fig. 2. After quality control, satisfactory 1H-MRS data of
48 patients and 21 controls were included for analysis. Of
the 48 patients, 25 had a low LVEF (mean, 31.2 %),
whereas the remaining 23 had a normal LVEF (mean,
60.2 %). The distribution of the clinical characteristics of
HF patients with low and normal LVEF was as follows:
history of ischemic heart disease, 32 and 35 %, respect-
ively; diabetes mellitus (DM), 58 and 74 %, respectively; di-
lated cardiomyopathy, 20 and 17 %, respectively; and
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myocarditis, 12 and 4 %, respectively. HF patients (either
with low or normal LVEF) did not differ significantly
from controls in terms of age, sex, body weight, and
body mass index (BMI; Table 1). The mean diastolic
blood pressure was significantly lower in both the low
LVEF (74.3 mmHg) and normal LVEF (73.7 mmHg)
groups than in controls (83.7 mmHg, p = 0.01). Serum
HDL levels were significantly higher in HF patients
with low LVEF (45.4 mg/dL) compared with the nor-
mal LVEF group (38.6 mg/dL, p = 0.02).
Fig. 2 Study flow chart. Summary of the patient selection algorithm and number of subjects in the three study groups: controls, HF (heart failure)
patients with low left ventricular ejection fraction (LVEF), and HF patients with normal LVEF
Fig. 1 Myocardial CMR spectroscopy. A 2 × 2 × 1-cm3 spectroscopic volume was acquired from the interventricular septum during the systolic phase
(left upper inset) to generate an input spectrum (left lower inset). 1H-CMR spectra were fitted and analyzed using the LC Model software (Provencher,
Ontario, CA, USA). We quantified the total myocardial TG resonance as well as its components – including fatty acids (FA, lipid resonances δ 0.9, 1.3,
and 1.6 ppm) and unsaturated fatty acids (UFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm). TMA, trimethyl amide
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CMR data
The CMR data of the study participants are summarized
in Table 2. Compared with controls, our low LVEF group
patients showed significant differences in all the functional
CMR parameters, including lower LVEF (31.2 % vs.
70.9 %), higher LVEDV (169.5 mL vs. 95.3 mL), higher
LVESV (120.8 mL vs. 28.2 mL), lower stroke volume
(48.7 mL vs. 67.2 mL), lower cardiac output (3.7 L/min vs.
5.1 L/min), higher LV mass (122.2 vs. 94.4) and lower
LVGFI (20.2 % vs. 46.2 %). Regarding our patients with
normal LVEF as compared with controls, significant differ-
ences were observed in LVEF, LVGFI, LVESV and LV mass
but not in LVEDV, stroke volume and cardiac output.
1H-MRS data
1H-MRS was found to be an accurate and reliable tech-
nique to quantify and discriminate between unsaturated
fatty acids and fatty acids in the phantom study (Additional
file 1: Figure S1). The Bland-Altman plots demonstrated
that the differences for FA and UFA lay within the mean ±
1.96 SD in the first ten control subjects, suggesting that
our results had an acceptable reproducibility [19] despite
large confidence intervals (Fig. 3). The coefficient of vari-
ation (CV) of the individual spectra acquired without water
suppression was 8 %, suggesting a robust and reproducible
measurement. The 1H-MRS characteristics of the study
participants are provided in Table 3. There were significant
differences in terms of myocardial UFA/W content among
the low LVEF group, the normal LVEF group, and controls
(0.79 % vs. 0.21 % vs. 0.14 %, p = 0.02), but no in terms of
TG/W and FA/W content. Moreover, the myocardial UFA/
W content was significantly higher in the low LVEF group
compared with the normal LVEF group (p = 0.03). The
myocardial UFA/TG ratio was strongly associated with LV














21 (84 %) 22 (96 %) 17
(81 %)
0.31
Age (years) 56.0 ± 7.7 56.1 ± 8.7 58.9 ±
7.2
0.39
Height (cm) 166.8 ± 8.6 165.8 ± 7.0 164.3 ±
5.0
0.48
Weight (kg) 71.6 ± 15.9 72.5 ± 12.0 70.9 ±
10.4
0.92
BMI (kg/m2) 25.5 ± 4.3 26.4 ± 4.1 26.3 ±
4.0
0.75


















189.8 ± 34.3 180.6 ± 31.7 178.4 ±
0.0
0.70










45.4 ± 10.1 38.6 ± 8.4 45.9 ±
25.6
0.14
T-cho/HDL 4.4 ± 1.3 4.9 ± 1.3 * 3.2 ± 2.0 0.04
LDL/HDL 2.7 ± 1.1 2.9 ± 1.1 3.3 ± 3.7 0.74
Non-HDL
(mg/dL)











6.4 ± 1.2 6.5 ± 1.5 * 4.1 ± 2.7 0.03
Data are expressed as means ± standard deviations. P values are calculated
from one-way analysis of variance
Abbreviations: HF, heart failure; LVEF left ventricular ejection fraction, BMI body
mass index, SBP systolic blood pressure, DBP diastolic blood pressure, DM
diabetes mellitus, MI prior myocardial infarction, DCM dilated cardiomyopathy,
HDL high-density lipoprotein cholesterol, T-cho total cholesterol VLDL very low-
density lipoprotein cholesterol, LVL low-density lipoprotein cholesterol, HbA1c
glycated hemoglobin
*p < 0.05 vs. controls








(n = 25) (n = 23) (n = 21)
LV ejection
fraction (%)




169.5 ± 78.1*,** 124 ± 43.7 * 95.3 ± 23.4 < 0.001
LV end-systolic
volume (mL)
120.8 ± 70.7*,** 51.2 ± 24.0 * 28.2 ± 11.5 < 0.001
Stroke
volume (mL)
48.7 ± 19.4*,** 72.8 ± 22.4 67.2 ± 15.9 < 0.001
Cardiac output
(L/min)
3.7 ± 1.5*,** 4.8 ± 1.5 5.1 ± 1.1 0.004




20.2 ± 9.0*,** 37.6 ± 6.7 * 44.6 ± 6.1 < 0.001
LV
concentricity
0.8 ± 0.3*,** 1.0 ± 0.4 1 ± 0.3 0.027
Data are expressed as means ± standard deviations. P values are calculated
from one-way analysis of variance
Abbreviations: HF heart failure, LV left ventricle, LVEF left ventricular
ejection fraction
*p < 0.05 vs. controls; **p < 0.05 vs. HF patients with normal LVEF
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mass (r = 0.39, p < 0.001) and modestly related to LVEDV
(r = 0.24, p = 0.039). We also identified negative correlations
of myocardial FA/TG ratio with both LV mass (r = -0.39,
p < 0.001) and LVEDV (r = -0.24, p = 0.039) (Table 4).
Discussion
1H-MRS performed on 1.5 T MR scanner has been
shown to be a reliable and reproducible imaging modal-
ity for the assessment of human myocardial TG content
[11–13], while the high-field 3 T MR scanner, as used in
this study, has significantly greater signal-to-noise ratio
coupled with increased spectral resolution and has
shown to be more accurate for in vivo quantification of
myocardial fat fraction as compared to 1.5-Tesla [20].
1H-MRS research study on formalin-fixed specimens of
human hearts at various locations demonstrated that
septal fat content is largely representative of myocardial
TG deposition [21]. Herein, we applied 1H-MRS in the
interventricular septum to assess the heart of a subgroup
of HF patients 6 ~ 12 months after hospitalization on 3-
T MR scanner. To the best of our knowledge, this is the
first in vivo study specifically investigating the relation of
different myocardial TG components and functional
cardiac parameters on post-hospitalized HF patients
with 3-T CMR plus 1H-MRS. Our main results indicated
an association between the accumulation of myocardial
TG components and the damaged heart. First, myocar-
dial UFA content was significantly higher in our patients
than in controls, even those showed good recovery from
HF with their LVEF restoring to the normal range. Sec-
ond, the myocardial UFA/TG ratio was positively corre-
lated with LV mass and LVEDV. The reproducibility of
our results was confirmed by Bland-Altman plots [19].
Taken together, the current study support the clinical
utility of 3 T 1H-MRS for measuring myocardial TG
components in patients who were hospitalized with
acute HF.
In this study, our patients had significantly increased
myocardial UFA content as compared with controls. In-
triguingly, there was a stepwise decrease of myocardial
UFA concentrations when comparing patients with low
LVEF, normal LVEF, and controls (p = 0.02). The stand-
ard deviation of UFA/W was significantly larger in pa-
tients with low EF compared with values observed in
patients with normal EF and controls (Table 3). This ob-
servation can be explained by the wider range of EF ob-
served in patients with low EF, ultimately resulting in a
higher standard deviation (12.3) than those observed in
both subjects with normal EF (8.3) and controls (7.6,
Table 2). The differences in the standard deviations are
unlikely to be caused by a suboptimal UFA quantifica-
tion. Accordingly, our phantom study clearly demon-
strated the reproducibility of measuring and fitting UFA
(Additional file: 1 Figure S1). The relationship of accumu-
lation of myocardial TG in patients with cardiomyopathy
has been previously reported, but with different results
[14, 15, 22, 23]. Graner et al. [22] reported that myocardial
TG content decreased in non-diabetic subjects with di-
lated cardiomyopathy, however, showed the opposite re-
sults in those with diabetic heart disease [14, 23]. Nakae
et al. [15] found that myocardial TG may be related to the
Fig. 3 Bland-Altman plot. Reproducibility between two repeated 1H-MRS measures within a single CMR session in the first 10 subjects regarding
(a) saturated fatty acid (FA) and (b) unsaturated fatty acid (UFA). Of note, two data points overlapped in the left lower corner on the UFA/W plot.
SD, standard deviation








(n = 25) (n = 23) (n = 21)
TG/W (%) 1.72 ± 2.63 1.18 ± 1.82 1.53 ± 1.78 0.68
FA/W (%) 0.93 ± 2.13 0.97 ± 1.64 1.39 ± 1.67 0.66
UFA/W (%) 0.79 ± 1.38*,** 0.21 ± 0.28 0.14 ± 0.20 0.02
FA/TG (%) 0.53 ± 0.41 0.68 ± 0.40 0.71 ± 0.32 0.25
UFA/TG (%) 0.47 ± 0.41 0.32 ± 0.40 0.29 ± 0.32 0.25
Data are expressed as means ± standard deviation. P values are calculated
from one-way analysis of variance
Abbreviations: HF heart failure, LVEF left ventricular ejection fraction, TG
triglyceride; FA fatty acids, UFA unsaturated fatty acids, W water
*p < 0.05 vs. controls; **p < 0.05 vs. HF patients with normal LVEF
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specific cause of disease rather than the severity of cardiac
dysfunction. Nevertheless, notable finding from the
current study is that myocardial UFA, instead of FA and
TG, was increased in post-hospitalized HF patients and
was related to the severity of LV systolic function.
LV mass and LVEDV of our patients were positively
correlated with myocardial UFA/TG ratio but were
negatively correlated with myocardial FA/TG ratio. Their
correlations with TG/W were not significant. In a series
of 15 healthy humans evaluated with 1.5 T 1H- MRS,
Szczepaniak et al. [24] found that increased myocardial
triglyceride content was accompanied by elevated LV
mass. In another series with ten male endurance athletes
and 15 healthy male controls evaluated with 1.5 T 1H-
MRS, Sai et al. [25] showed that the myocardial TG con-
tent was significantly lower in the athlete group than in
the control group, and was negatively correlated with LV
mass and volume. We believe that the study participants
selection and MRI scanner field strength may, at least,
partly account to the discrepancies of our results from
those previously reported. Of note, the averaged TG/W
ratio found in our control group was 15.3 which fell be-
tween those of our stable HF (11.8) and unstable HF
group (17.2). Accordingly, our control subjects had a
mean body mass index of 26.3 kg/m2, being overweight
according to the WHO definition. In addition, the TG/
W ratio is characterized by a diurnal course, with higher
levels in the morning than in the evening [9]. The im-
pact of these potential confounders on the TG/W needs
further scrutiny.
It has been reported that myocardial TG accumulation
promotes the development of cardiac hypertrophy, ven-
tricular dysfunction, and interstitial fibrosis [5]. Al-
though an increased TG deposition in the pancreatic
islets has been linked to non-insulin-dependent diabetes
mellitus [26], the potential relationship between myocar-
dial TG accumulation and diabetic heart disease remains
unclear. An animal study has demonstrated that in-
creased TG content within the myocardium contributes
to the development of cardiac dysfunction through lipo-
toxic effects [27]. In patients with HF, accumulation of
myocardial UFA may reflect a switch of the myocardial
Table 4 Correlations (Spearman’s rho) between the myocardial TG
components and CMR features




TG/W (%) LVEF (%) 0.024 0.85
LVEDV (mL) −0.007 0.95











LV concentricity −0.280 0.02
FA/W (%) LVEF (%) 0.161 0.19
LVEDV (mL) −0.194 0.11
LVESV (mL) −0.188 0.12









LV concentricity −0.146 0.23
UFA/W (%) LVEF (%) −0.177 0.15
LVEDV (mL) 0.170 0.16
LVESV (mL) 0.216 0.07








LV concentricity −0.253 0.04
FA/TG (%) LVEF (%) 0.176 0.15
LVEDV (mL) −0.218 0.07
LVESV (mL) −0.233 0.05








LV concentricity −0.038 0.75
UFA/TG (%) LVEF (%) −0.178 0.14
LVEDV (mL) 0.219 0.07
LVESV (mL) 0.234 0.05
LV stroke volume 0.092 0.45
Table 4 Correlations (Spearman’s rho) between the myocardial TG








LV concentricity 0.056 0.65
Abbreviations: TG triglyceride, FA fatty acids, UFA unsaturated fatty acids, W
water, LVEF left ventricular ejection fraction, LVEDV left ventricular end-
diastolic volume, LVESV left ventricular end-systolic volume, LV left ventricle
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energy metabolism to the fetal transcriptional program
with a reduced rate of β-oxidation, which is partially
compensated by an increased of glucose utilization [28].
Moreover, Lahey et al. have shown that UFA are more
potent activators of TG turnover than saturated FA in
animal models. In decompensated HF, UFA may serve as
a beneficial energy substrate versus FA by upregulating
TG dynamics and nuclear receptor signaling [29]. Not-
withstanding the scarce evidence, it has been alterna-
tively suggested that myocardial TG accumulation may
be protective against fatty acid-induced lipotoxicity by
limiting the deposition of ceramides and diacylglycerols
[30, 31]. Although our study did not provide the mecha-
nisms how TG content mediates cardiac dysfunction,
the in vivo identification of the associations of TG com-
ponents, particularly UFA, with cardiac function using
3-T CMR in the post-treated failed heart is an important
step forward.
The mean BMI of the entire study population (compris-
ing both patients and controls) was 26.1 kg/m2, suggesting
the presence of overweight according to the World Health
Organization criteria [32]. Previous studies have linked
the presence of cardiac steatosis with obesity and related
metabolic diseases [10, 16, 17]. Notably, ectopic TG accu-
mulation within and around the myocardium in moder-
ately obese individuals has been associated with free
fatty acid exposure, generalized ectopic fat excess,
and peripheral vascular resistance [33]. However, we
failed to identify significant associations between
myocardial TG content and serum lipid levels. These
results suggest that 1H-MRS measurements of myo-
cardial TG content may provide complementary clin-
ical information beyond serum lipid profile.
Limitations
Several caveats of our study merit comment. First, our
subgroup analysis is limited by the small sample size. Al-
though myocardial UFA/TG was positively related with
LV mass and LVEDV, these relationships were fairly
weak (r = 0.39 and 0.24, respectively) and large confi-
dence intervals for the spectral quantification were evi-
dent. Therefore, caution should be exercised in the
interpretation of our findings. Future larger studies will
be needed to establish whether myocardial UFA content
may vary between HF patients with different etiologies.
Second, 1H-MRS measurements of myocardial TG
content were not validated by histological examin-
ation of biopsies, mainly because of ethical concerns.
Finally, it is unclear whether the accumulation of
myocardial TG results from increased uptake of fatty
acids, higher de novo lipogenesis, or reduced lipid
degradation. Further studies are required to clarify
the pathophysiological mechanisms of myocardial TG
accumulation in HF patients.
Conclusions
Patients who were discharged after hospitalization for
acute HF had increased myocardial UFA content as
compared with controls. Furthermore, UFA was in-
versely related with LVEF, LV mass and, to a lesser ex-
tent, LVEDV. Our current report may stimulate further
research aimed at measuring myocardial UFA content by
1H-MRS for predicting clinical outcomes.
Additional file
Additional file 1: Figure S1. MRS of an oil phantom. Representative
magnetic resonance spectrum of an oil phantom (85 % unsaturated fatty
acid) at 3 T, with a 2 × 2 × 1-cm3 spectroscopic volume. 1H-MR spectra
were analyzed using the LC Model software. Fatty acids (FA, lipid
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